Skip to content

Choroidal Response to the Modified Defocus Incorporated Multiple Segments Spectacle Lenses

Choroidal Responses to the Modified Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07547072
Enrollment
108
Registered
2026-04-23
Start date
2026-04-24
Completion date
2028-02-29
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Myopia, Choroidal thickness

Brief summary

The goal of this study is to investigate the short-term changes in choroidal thickness and efficacy of the study spectacle lenses in children. Participants will be prescribed with a pair of study spectacle lenses for daily use and visit the clinic once every week for the first month for checkup and tests. After the first month of follow-up, participants will visit at 1 month, 6- and 12-month for checkup. Choroidal thickness, axial length and refractive errors will be monitored.

Detailed description

Optical interventions have been widely used for myopia control in children, however, the effectiveness varied between individuals. The current study spectacle lenses are modified based on DIMS technology. Participants will be randomly allocated to single vision (SV) lens group (control), D1 or D2 group (treatment). The weekly choroidal thickness changes will be monitored in the first month of lens wear. Their cycloplegic refraction and axial length will be monitored every 6 months for 1 year.

Interventions

OTHERModified Defocus Incorporated Multiple Segments lens (D1)

D1 is a modified Defocus Incorporated Multiple Segments lens that corrects the distance refraction and provides myopic defocus simultaneously

OTHERModified Defocus Incorporated Multiple Segments lens (D2)

D2 is a modified Defocus Incorporated Multiple Segments lens that corrects the distance refraction and provides myopic defocus simultaneously

Sponsors

The Hong Kong Polytechnic University
Lead SponsorOTHER
HOYA Lens Thailand LTD.
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Both participants and their guardians will be masked from the grouping. The outcomes assessors will be also masked from the grouping.

Eligibility

Sex/Gender
ALL
Age
6 Years to 13 Years
Healthy volunteers
Yes

Inclusion criteria

* Hong Kong Chinese * Age at enrolment: 6 - 13 years * Myopia in spherical power: -1.00D to -5.00D in both eyes * Astigmatism: equal or less than 2.00D * The sum of spherical power and astigmatism: equal or less than -7.00D * Anisometropia (spherical equivalent refraction (SER)): equal or less than 1.50D * Previous myopia progression (valid documentation dated within 2 years before screening): * -0.50D (SER) per year or more in both eyes OR Axial length elongation: 0.27mm/year in both eyes * If myopia is initially detected during screening, eligibility requires myopia (in SER) below the 3rd percentile curve of refraction in both eyes.12 * Best corrected visual acuity: LogMAR 0.04 or better in both eyes * Ocular health: no abnormalities in both internal and external ocular health * Binocular vision: no strabismus and other binocular abnormalities * Normal colour vision * Willing to wear the study spectacles all the time (10 hours per day, for 7 days per week)

Exclusion criteria

* Previous or current treatment for myopia control (e.g., red-light therapy, atropine, orthokeratology, specialized spectacle lenses and contact lenses and oral supplements for myopic control) * Existing or past eye diseases or surgeries (e.g., strabismus surgery, amblyopia, oculomotor nerve palsies, corneal disease, intraocular disease, etc.) that may have an impact on vision or visual development * Long-term medication (intake at least 3 days/week) or medication/supplements that affect eye health * Systemic diseases that may have an impact on vision or visual development (e.g., endocrine, cardiac and respiratory diseases, diabetes, Down syndrome, etc.) * Allergic to cyclopentolate eye drops * Individuals who, in the judgment of the Investigator, are unable to cooperate and follow instructions during eye examination.

Design outcomes

Primary

MeasureTime frameDescription
Choroidal thickness changesBaseline, every week for 1 month, every 6 months over 1 yearChoroidal thickness will be measured by a swept source optical coherence tomographer. Changes in choroidal thickness from baseline over the first month and every 6 months for 1 year over the study period.

Secondary

MeasureTime frameDescription
Cycloplegic refraction change in spherical equivalent refraction (SER)Baseline, 6 and 12 monthsCycloplegic SER (in diopter) will be measured using an open field autorefractor. Change in SER with cycloplegia from the baseline every 6 months for 1 year over the study period.
Axial length changesBaseline, 6 and 12 monthsAxial length (mm) will be measured after cycloplegia using a non-contact optical biometer. Change in axial length from the baseline every 6 months for 1 year over the study period.

Countries

Hong Kong

Contacts

CONTACTRachel Ka Man Chun, PhD
rachel.chun@polyu.edu.hk852-27664224
CONTACTDennis Yan Yin Tse, PhD
dennis.tse@polyu.edu.hk852-27666096
PRINCIPAL_INVESTIGATORRachel Ka Man Chun, PhD

School of Optometry, The Hong Kong Polytechnic University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026